High expression of a disintegrin and metalloproteinase-9 predicts a shortened survival time in completely resected stage I non-small cell lung cancer

Oncology Letters

Volumn 5, Issue 5, 2013, Pages 1461-1466

  Zhang, Jun ^a   Qi, Juan ^a   Chen, Ning ^a,b   Fu, Weineng ^a,c   Zhou, Baosen ^a,c   He, Anguang ^a,c  

^a China Medical University Lung Cancer Center   (China)

^b LIAONING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c CHINA MEDICAL UNIVERSITY   (China)

Author keywords

ADAM9; Immunohistochemistry; Lobectomy; Lung neoplasm; Prognosis

Indexed keywords

ADAM9 ENDOPEPTIDASE; METALLOPROTEINASE; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCUBATION TIME; LOBECTOMY; LUNG NON SMALL CELL CANCER; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; SCORING SYSTEM; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; SURVIVAL TIME;

EID: 84875756929     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1209     Document Type: Article

References (25)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA: Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83: 584-594, 2008.
3. Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest 111: 1710-1717, 1997.
4. Nesbitt JC, Putnam JB Jr, Walsh GL, Roth JA and Mountain CF: Survival in early-stage non-small cell lung cancer. Ann Thorac Surg 60: 466-472, 1995.
5. Seals DF and Courtneidge SA: The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 17: 7-30, 2003.
6. Fischer OM, Hart S, Gschwind A, Prenzel N and Ullrich A: Oxidative and osmotic stress signaling in tumor cells is mediated by ADAM proteases and heparin-binding epidermal growth factor. Mol Cell Biol 24: 5172-5183, 2004.
7. Hirao T, Nanba D, Tanaka M, Ishiguro H, Kinugasa Y, DokiY, Yano M, Matsuura N, Monden M and Higashiyama S: Overexpression of ADAM9 enhances growth factor-mediated recycling of E-cadherin in human colon cancer cell line HT29 cells. Exp Cell Res 312: 331-339, 2006.
8. Mahimkar RM, Visaya O, Pollock AS and Lovett DH: The disintegrin domain of ADAM9: a ligand for multiple beta1 renal integrins. Biochem J 385: 461-468, 2005.
9. O'Shea C, McKie N, Buggy Y, Duggan C, Hill AD, McDermottE, O'Higgins N and Duffy MJ: Expression of ADAM-9 mRNA and protein in human breast cancer. Int J Cancer 105: 754-761, 2003.
10. Tannapfel A, Anhalt K, Häusermann P, Sommerer F, BenickeM, Uhlmann D, Witzigmann H, Hauss J and Wittekind C: Identification of novel proteins associated with hepatocellular carcinomas using protein microarrays. J Pathol 201: 238-249, 2003.
11. Carl-McGrath S, Lendeckel U, Ebert M, Roessner A and RöckenC: The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. Int J Oncol 26: 17-24, 2005.
12. Grützmann R, Lüttges J, Sipos B, Ammerpohl O, DobrowolskiF, Alldinger I, Kersting S, Ockert D, Koch R, Kalthoff H, SchackertHK, Saeger HD, et al: ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Br J Cancer 90: 1053-1058, 2004.
13. Fritzsche FR, Jung M, Tölle A, Wild P, Hartmann A, WassermannK, Rabien A, Lein M, Dietel M, Pilarsky C, CalvanoD, Grützmann R, et al: ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. Eur Urol 54: 1097-1106, 2008.
14. Fritzsche FR, Wassermann K, Jung M, Tölle A, Kristiansen I, Lein M, Johannsen M, Dietel M, Jung K and Kristiansen G: ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression. BMC Cancer 8: 179, 2008.
15. Zubel A, Flechtenmacher C, Edler L and Alonso A: Expression of ADAM9 in CIN3 lesions and squamous cell carcinomas of the cervix. Gynecol Oncol 114: 332-336, 2009.
16. Qi J and Zhang J: Abnormal expression of ADAM9 in non-small cell lung cancers. Zhongguo Yike Daxue Xuebao 39: 670-671, 2010 (In Chinese).
17. Zhang J, Qi J, Chen N, Guo Y, Fu W, Zhou B and He A: Highly expressed ADAM9 in completed resected stage I non-small cell lung cancer cases predicts a shortened survival. J Thorac Oncol 6: s1068-s1069, 2011.
18. Shintani Y, Higashiyama S, Ohta M, Hirabayashi H, YamamotoS, Yoshimasu T, Matsuda H and Matsuura N: Overexpression of ADAM9 in non-small cell lung cancer correlates with brain metastasis. Cancer Res 64: 4190-4196, 2004.
19. Zhang J, Ren H, Yuan P, Lang W, Zhang L and Mao L: Down-regulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells. Cancer Res 66: 18-23, 2006.
20. Zhang J and Mao L: SiRNA targeting hepatoma-derived growth factor (HDGF) inhibits growth of non-small cell lung cancer in xenograft models. Tumor Biology 35: Emerging Molecules, Mechanisms, and Models. Proc Amer Assoc Cancer Res 47: abstract #5135, 2006.
21. Zhang J, Qi J, Guo Y, Guo Y, Fu W, Zhou B, Wu G, Han L and He A: Aberrant expression of HDGF and its prognostic values in surgically resected non-small cell lung cancer. Zhongguo Fei Ai Za Zhi: 211-218, 2011 (In Chinese).
22. Besse B and Le Chevalier T: Adjuvant chemotherapy for non-small-cell lung cancer: a fading effect? J Clin Oncol 26: 5014-5017, 2008.
23. Douillard JY and Gauducheau CR: Adjuvant chemotherapy for non-small-cell lung cancer: it does not always fade with time. J Clin Oncol 28: 3-5, 2010.
24. Zhu CQ, Ding K, Strumpf F, Weir BA, Meyerson M, Pennell N, Thomas RK, Naoki K, Ladd-Acosta C, Liu N, Pintilie M, DerS, et al: Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol 28: 4417-4424, 2010.
25. Xie Y and Minna JD: Non-small-cell lung cancer mRNA expression signature predicting response to adjuvant chemotherapy. J Clin Oncol 28: 4404-4407, 2010.